Factor VII

• 

  Subject Areas on Research

  • A radioreceptor assay for quantitating plasma factor VIII/von Willebrand's protein. 
  • Avoiding Cardiovascular Collapse: Pediatric Cutaneous Mastocytosis and Anesthetic Challenges. 
  • Challenges for providing effective hemostasis in surgery and trauma. 
  • Cloning and characterization of the 5' end (exon 1) of the gene encoding human factor X. 
  • Coagulopathy and inflammation in neonatal heart surgery: mechanisms and strategies. 
  • Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. 
  • Fatal Thrombosis After Factor VII Administration During Extracorporeal Membrane Oxygenation. 
  • Hemostatic properties of the FVIIa analog NN1731. 
  • Laboratory monitoring of high-dose factor VIIa therapy. 
  • Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. 
  • Massive transfusion coagulopathy. 
  • Monitoring direct thrombin inhibitors: time for standardization. 
  • NovoSeven for non-hemophilia hemostasis. 
  • Orphan nuclear receptor HNF-4 binds to the human coagulation factor VII promoter. 
  • Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. 
  • Population genetic and phylogenetic evidence for positive selection on regulatory mutations at the factor VII locus in humans. 
  • Procoagulant and platelet aggregating properties of antilymphocyte sera. 
  • Recombinant activated factor VII and the anaesthetist. 
  • Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. 
  • Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. 
  • Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. 
  • Safety profile of recombinant factor VIIa. 
  • Sphingosine inhibits monocyte tissue factor-initiated coagulation by altering factor VII binding. 
  • Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. 
  • The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. 
  • The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. 
  • The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. 
  • Thrombotic complications after substitution with a FVII concentrate. 
  • Tissue factor around dermal vessels has bound factor VII in the absence of injury. 
  • Variations of cardiovascular disease associated genes exhibit sex-dependent influence on human longevity. 
• 

  Keywords of People

  • Hoffman, Maureane, Professor of Pathology, Immunology
  • Levy, Jerrold Henry, Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • Swaminathan, Madhav, Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • Wray, Gregory Allan, Professor of Biology, Duke Innovation & Entrepreneurship